Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Cytokinetics Reports Results From Phase II Clinical Trials Evaluating CK-2017357

Cytokinetics, Inc. (CYTK: Quote) announced encouraging results from two Phase II clinical trials evaluating CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

Jeremy Shefner, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York, concluded that CK-2017357 appeared to be safe and well-tolerated dosed daily at 125 mg, 250 mg, and 375 for two weeks, and that encouraging trends were observed in the ALSFRS-R and MVV. As expected, plasma concentrations of CK-2017357 were unaffected by co-administration with riluzole, while riluzole levels increased during co-administration with CK-2017357.

Adverse events and clinical assessments during treatment with CK-2017357 appeared similar, with or without co-administration of riluzole at the reduced dose of 50 mg daily. Dizziness, the most commonly reported adverse event, was mostly mild and generally began and resolved early after initiating treatment.

Click here to receive FREE breaking news email alerts for Cytokinetics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
U.K. retail sales increased only marginally in June on weak clothing sales as stores delayed summer clearances due to good weather, data from the Office for National Statistics showed Thursday. However, retail sales during the second quarter hit a 10-year high, signaling strong support from consumer demand to overall economic growth. After ending the previous session mixed, stocks are likely to move to the upside in early trading on Thursday. The major index futures are currently pointing to a modestly higher open for the markets, with the Dow futures up by 24 points. The Eurozone private sector growth rebounded at the start of the third quarter from a six-month low as strong expansion in Germany neutralized the contraction in France. The flash composite output index rose to 54 in July to match April's three-year high level, flash survey data from Markit Economics showed Thursday. A reading above 50 indicates expansion in the private sector.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.